Szarkóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• EGFR 1
• JAK 1
• PARP 4
• YAP 0
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• CXCR4 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• FLT3 0
• FTO 0
• HDAC 0

3+ intézményből 3, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  Novel gene mutation agnostic small molecule to treat retinitis pigmentosa

  Mitochem Therapeutics Inc.· Charleston, Egyesült Államok· 320 790 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, Egyesült Államok· 37 011 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, Egyesült Államok· 785 081 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, Egyesült Államok· 350 188 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R16

  Mechanisms of lymphoma cell dissemination to the brain

  North Park University· Chicago, Egyesült Államok· 162 527 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  immunoTHErapies targeting neOgenes in paeDiatric and adOlescent saRcomAs (THEODORA)

  Institut Curie· Paris, Franciaország· EU contribution 8 712 800 EUR· until 2032. febr.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 2 302 626 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spanyolország· EU contribution 194 075 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Pioneering antibody-drug conjugates targeting the tumour microenvironment to deliver transformative new therapies in oncology (ONCO-DART)

  Oncomatryx Biopharma Sa· Derio, Spanyolország· EU contribution 2 499 376 EUR· until 2027. okt.

  The disease is named only in the funder's project summary, not in the title.

10 of 1624 running projects, newest first. Listed amounts together: 944,4 M USD + 86,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 153
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 198
• Machine Learning 29
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability.

  Hum Cell, 2026. aug.

• Establishment of a ZFP64::NCOA3 fusion-positive spindle cell/sclerosing rhabdomyosarcoma organoid model and evaluation of fusion-gene dependency.

  Hum Cell, 2026. aug.

• Engineering cell ring organoids for efficient establishment of patient-derived orthotopic xenotransplantation (r-PDOX) model in sarcoma.

  Biomaterials, 2026. jún.

• Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy.

  Cell Rep Med, 2026. febr.

• Single-Cell Mitochondrial Lineage Tracing Decodes Fate Decision and Spatial Clonal Architecture in Human Hematopoietic Organoids.

  Adv Sci (Weinh), 2026. jan.

• High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

  J Exp Clin Cancer Res, 2026. jan.

• Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression.

  Sci Rep, 2025. dec.

• Chondrosarcoma organoids reveal SHH pathway activation driven by PTCH1 and BCOR alterations.

  Sci Rep, 2025. dec.

• Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential.

  J Exp Clin Cancer Res, 2025. dec.

• Highly Tunable and Cell-Remodelable Thiol-ene Alginate-Peptide Crosslinked Hydrogels to Recreate Cellular and Organoid Microenvironments for Biofabrication.

  Adv Healthc Mater, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.